SODIUM NITROPRUSSIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sodium Nitroprusside, and when can generic versions of Sodium Nitroprusside launch?
Sodium Nitroprusside is a drug marketed by Abraxis Pharm, Amneal, Amphastar Pharms Inc, Avet Lifesciences, Baxter Hlthcare, Be Pharms, Caplin, Chartwell Rx, Cipla, Dr Reddys, Epic Pharma Llc, Eugia Pharma, Hainan Poly Pharm, Micro Labs, Mylan, Mylan Labs Ltd, Nexus, Sagent Pharms Inc, Somerset Theraps Llc, Sun Pharm, Teva Parenteral, Xiromed, and Hainan Poly. and is included in twenty-three NDAs.
The generic ingredient in SODIUM NITROPRUSSIDE is sodium nitroprusside. There are one thousand four hundred and seventy-two drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the sodium nitroprusside profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sodium Nitroprusside
A generic version of SODIUM NITROPRUSSIDE was approved as sodium nitroprusside by SAGENT PHARMS INC on December 8th, 2016.
Summary for SODIUM NITROPRUSSIDE
| US Patents: | 0 |
| Applicants: | 23 |
| NDAs: | 23 |
| Finished Product Suppliers / Packagers: | 15 |
| Raw Ingredient (Bulk) Api Vendors: | 42 |
| Clinical Trials: | 76 |
| Patent Applications: | 38 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for SODIUM NITROPRUSSIDE |
| DailyMed Link: | SODIUM NITROPRUSSIDE at DailyMed |
Recent Clinical Trials for SODIUM NITROPRUSSIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Egymedicalpedia | Early Phase 1 |
| Tanta University | N/A |
| Kafrelsheikh University | N/A |
Pharmacology for SODIUM NITROPRUSSIDE
| Drug Class | Vasodilator |
| Physiological Effect | Vasodilation |
Anatomical Therapeutic Chemical (ATC) Classes for SODIUM NITROPRUSSIDE
US Patents and Regulatory Information for SODIUM NITROPRUSSIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abraxis Pharm | SODIUM NITROPRUSSIDE | sodium nitroprusside | INJECTABLE;INJECTION | 070031-001 | Jan 17, 1985 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Sagent Pharms Inc | SODIUM NITROPRUSSIDE | sodium nitroprusside | INJECTABLE;INJECTION | 207426-001 | Dec 8, 2016 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Hainan Poly | SODIUM NITROPRUSSIDE | sodium nitroprusside | SOLUTION;INTRAVENOUS | 215846-002 | Aug 26, 2022 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Caplin | SODIUM NITROPRUSSIDE | sodium nitroprusside | INJECTABLE;INJECTION | 211016-001 | Nov 29, 2019 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
